AXIOMScientific Capital

Scientific assets registered on AXIOM Scientific Capital

Scientific assets, structured like financial instruments.

Each asset carries only what is documented: asset type, scientific area, development phase, TRL, technical viability and licensing availability. Evidence, intellectual property and indicative valuation are published as each dossier is validated.

19 / 19 assets

AXW-001
TRL 7Licensing open

Oral-dissolving solid matrix technology platform — functional no-added-sugar lollipop containing protected lactase

Delivery platforms · Platform

Industrial scale-up — Process transfer, stability and regulatory dossier.

Phase
Phase 3
Viability
82/100
Projected valuation
US$ 3.9M – US$ 15M
AXW-002
TRL 6Licensing open

AURA HEALTH FINANCE — Behavioral Health & Financial Intelligence Platform

Health AI & fintech · Platform

Field pilot — Protocol running in real environment / cohorts.

Phase
Phase 3
Viability
74/100
Projected valuation
US$ 7.9M – US$ 31M
AXW-003
TRL 5Licensing open

ABIP Nutritional Phytochemical Platform™

Nutritional platforms · Platform

Scientific validation — Laboratory and analytical evidence in consolidation.

Phase
Phase 2
Viability
68/100
Projected valuation
US$ 1.9M – US$ 7.6M
AXW-004
TRL 6

ABIP — Pilot study protocol for nutritional intervention and field validation

Clinical protocols · Protocol

Field pilot — Protocol running in real environment / cohorts.

Phase
Phase 3
Viability
71/100
Projected valuation
US$ 1.1M – US$ 4.5M
AXW-005
TRL 4

ABIP — Multicomponent functional nutritional formulation for intervention in child malnutrition (ownership-corrected version)

Nutritional formulations · Formulation

IP filed — Filed for protection, before technical validation.

Phase
Phase 2
Viability
63/100
Projected valuation
US$ 800k – US$ 3.1M
AXW-006
TRL 5Licensing open

ABIP — Multicomponent functional nutritional formulation for intervention in child malnutrition

Nutritional formulations · Formulation

Scientific validation — Laboratory and analytical evidence in consolidation.

Phase
Phase 2
Viability
66/100
Projected valuation
US$ 1M – US$ 3.9M
AXW-007
TRL 6

ABIP — Integrated platform for nutritional, cognitive and bioeconomic intervention in a real-world setting (SUS)

Public health systems · Platform

Field pilot — Protocol running in real environment / cohorts.

Phase
Phase 3
Viability
70/100
Projected valuation
US$ 5M – US$ 20M
AXW-008
TRL 5Licensing open

BioCurauá Project — Curauá gM GlucoCare

Bioeconomy · R&D project

Scientific validation — Laboratory and analytical evidence in consolidation.

Phase
Phase 2
Viability
64/100
Projected valuation
US$ 700k – US$ 2.7M
AXW-009
TRL 4Licensing open

CannabiMod-P™ Onco

Biopharma · Technology

Scientific validation — Laboratory and analytical evidence in consolidation.

Phase
Phase 2
Viability
58/100
Projected valuation
US$ 2.2M – US$ 8.7M
AXW-010
TRL 3

CellRex™ Cellular Reprogrammer for Nutritional Rehabilitation

Cell science · Technology

IP filed — Filed for protection, before technical validation.

Phase
Phase 1
Viability
52/100
Projected valuation
US$ 200k – US$ 800k
AXW-011
TRL 4Licensing open

NutraSeq™

Precision nutrition · Technology

Scientific validation — Laboratory and analytical evidence in consolidation.

Phase
Phase 2
Viability
61/100
Projected valuation
US$ 1M – US$ 4M
AXW-012
TRL 5Licensing open

ImmunoAfrica™

Global health · R&D project

Field pilot — Protocol running in real environment / cohorts.

Phase
Phase 3
Viability
67/100
Projected valuation
US$ 1.8M – US$ 7.2M
AXW-013
TRL 6Licensing open

ZimKids Cognition™

Cognitive health · R&D project

Field pilot — Protocol running in real environment / cohorts.

Phase
Phase 3
Viability
69/100
Projected valuation
US$ 1.6M – US$ 6.5M
AXW-014
TRL 5Licensing open

NutraRegen™ Adaptive Metabolic Modulator for Severe Malnutrition and Cachexia

Metabolic science · Formulation

Scientific validation — Laboratory and analytical evidence in consolidation.

Phase
Phase 2
Viability
65/100
Projected valuation
US$ 850k – US$ 3.5M
AXW-015
TRL 8Licensing open

HERBAL SCIENCE For Men's Health

Consumer health · Product

Market ready — Commercially deployable, licensing open.

Phase
Phase 4
Viability
88/100
Projected valuation
US$ 7M – US$ 28M
AXW-016
TRL 8Licensing open

Improve For Man Line — Inovattis Health Science

Consumer health · Product

Market ready — Commercially deployable, licensing open.

Phase
Phase 4
Viability
85/100
Projected valuation
US$ 6M – US$ 24M
AXW-017
TRL 7Licensing open

Brain Kids Global Project — Child cognitive and emotional supplementation with international scientific validation

Cognitive health · R&D project

Industrial scale-up — Process transfer, stability and regulatory dossier.

Phase
Phase 3
Viability
78/100
Projected valuation
US$ 3.6M – US$ 14M
AXW-018
TRL 4Licensing open

NitraBeet™ — Cardiovascular bioactive complex of natural beetroot nitrates and nitrites with encapsulated magnesium

Cardiovascular science · Formulation

Scientific validation — Laboratory and analytical evidence in consolidation.

Phase
Phase 2
Viability
62/100
Projected valuation
US$ 1.5M – US$ 6.2M
AXW-019
TRL 3

NeuroFlow Kids™ — Support technology for child neurocognitive development in dyslexia and related difficulties

Child neurocognition · Technology

Scientific validation — Laboratory and analytical evidence in consolidation.

Phase
Phase 2
Viability
54/100
Projected valuation
US$ 450k – US$ 1.9M

Model-based projection derived from the global size of the problem and data available in the literature, weighed against AXIOM's viability of building and delivering the solution. Indicative estimate based on the AXIOM methodology and information available as of the valuation date. It does not constitute an independent valuation, offering price, investment recommendation, or guarantee of future value.